DOCSLIB.ORG

Memoria 2019, El Plan De Actuación 2019, Los Presupuestos De IDIVAL 2019 Y Ha Realizado Evaluación De Seguimiento De Cinco Grupos IDIVAL

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Memoria 2019, El Plan De Actuación 2019, Los Presupuestos De IDIVAL 2019 Y Ha Realizado Evaluación De Seguimiento De Cinco Grupos IDIVAL Memoria de Actividad 03 IDIVAL el Instituto de Investigación Sanitaria de Cantabria Llevamos la investigación en nuestro ADN Desde 1929 04 Memoria de Actividad Índice ÍndiceIDIVAL is... CONSEJERкA DE SANIDAD Edita: IDIVAL Depósito Legal: SA 525-2015 Instituto de Investigación Marqués de Valdecilla Avda. Cardenal Herrera Oria s/n 39011 Santander – España 05 Prólogo 08 Valdecilla 13 IDIVAL 15 Estructura Organizativa 17 Apoyo a los investigadores 25 Formación 45 Algunos Hitos de 2019 55 Actividad I+D+i IDIVAL 63 Áreas de Investigación: 131 > Área de Trasplante de Órganos y Tejidos, y Nuevas Terapias 133 > Área de Neurociencias 173 > Área de Cáncer 199 > Área de Transversal 241 > Área de Enfermedades Infecciosas y Sistema Inmune 269 > Área de Metabolismo, Enfermedades del Envejecimiento y Hábitos de Vida 297 > Grupos Asociados 307 07 Prólogo 08 Memoria de Actividad Prólogo Nuestro sistema sanitario, con el Hospital Universitario una excelente base para el desarrollo de proyectos de Marqués de Valdecilla al frente, es sin duda un elemento investigación y es muy notorio el programa de ayudas que genera enorme valor para toda la Comunidad a la investigación, que posiciona al IDIVAL como un Autónoma; tanto en su objetivo central, que es el de referente a nivel nacional en esta materia y que es prevención, cuidado y curación de los pacientes, como posible gracias a la confianza y al apoyo económico del por el valor socieconómico que aportan los más de Gobierno de Cantabria. 10.000 puestos de trabajo activos y la adquisición de costosos bienes necesarios para realizar esta labor IDIVAL sigue creciendo, ampliando sus objetivos y asistencial. tratando de aportar soluciones reales a los problemas de salud de los pacientes. La producción científica de Pero no nos debemos olvidar de otro gran activo que IDIVAL crece año a año, como lo hace su repercusión se genera en nuestro entorno gracias a la participación en la literatura internacional y, siendo esto importante, directa de pacientes y profesionales, que es el lo realmente valioso es que este conocimiento nos sirve conocimiento y su aplicación, fruto de la investigación para mejorar la atención de los pacientes. La aplicación e innovación en salud, en la que el Instituto de de ese conocimiento a través de guías de práctica Investigación Marqués de Valdecilla (IDIVAL) tiene un clínica publicadas en revistas de prestigio, es sin duda papel relevante. un buen ejemplo de como nuestros investigadores aportan un valor extra a la atención sanitaria. Este año 2019 se han cumplido cinco años desde la constitución de IDIVAL como Fundación por decisión Dos mil diecinueve ha sido un año de especial del Gobierno de Cantabria y de la Universidad de relevancia en el crecimiento de la cantidad y calidad Cantabria, hecho que se siguió de su acreditación de los ensayos clínicos realizados en nuestro sistema como Instituto de Investigación Sanitaria por el sanitario. El Hospital Universitario Marqués de Valdecilla Instituto de Salud Carlos III en 2015. En este tiempo de la mano de grandes expertos clínicos de diferentes IDIVAL se ha consolidado como un elemento central servicios y con el soporte de la unidad de ensayos dinamizador de la investigación e innovación sanitarias clínicos se ha consolidado en la realización de ensayos de Cantabria, con recursos de soporte especializado que clínicos de alta complejidad, estudios que son altamente han permitido abordar proyectos ambiciosos. IDIVAL exigentes y requieren el máximo rigor asistencial e cuenta con unidades de soporte en gestión, servicios investigador, en la medida que implican aplicación de tecnológicos y un edificio con laboratorios que son nuevas terapias a pacientes. Estos mismos ensayos son 09 una fuente de nuevas opciones terapéuticas, una fuente sus facetas se ha convertido en una oportunidad – y de ingresos para el desarrollo de investigación clínica y también en una obligación si queremos mantener la una fuente de prestigio. Para seguir avanzando en esta calidad de nuestro sistema sanitario – y su potenciación línea debemos hacer un esfuerzo de modernización y reconocimiento de la mano de los profesionales es de los recursos de soporte que esta Consejería ha otro de nuestros retos. Ya contamos con potentes comprometido y que deben permitirnos ser una vez más recursos de soporte para la innovación en IDIVAL, la centro de referencia, esta vez en investigación clínica. excelente oportunidad de compartir conocimiento y recursos que nos da la plataforma de innovación en Este año también ha sido un año de reflexión y análisis tecnologías médicas y sanitarias ITEMAS, plataforma para IDIVAL en la medida en que debía renovar la que coordinamos a nivel Nacional, y con una magnifica acreditación como Instituto de Investigación Sanitaria, disposición de profesionales y equipos directivos que con una nueva guía de acreditación que añade deben servir para ahondar en las posibilidades que nos importantes exigencias a las ya existentes previamente. da el emprendimiento corporativo. La visita de los auditores del Instituto de Salud Carlos III ha permitido testar de cerca la magnífica disposición de La responsabilidad de dirigir un sistema sanitario como la inmensa mayoría de nuestros investigadores a apoyar el nuestro pasa también, y quizá sobre todo, por abrir este proyecto compartido y que desde esta Consejería puentes, fomentar sinergias, crear los canales adecuados agradecemos. Esta visita, con un resultado satisfactorio, con todos los agentes de nuestra sociedad a nivel local, también nos ha permitido encarar de cerca los retos regional, nacional e internacional y facilitar que éstos, de nuestro Instituto que sin duda tienen mucho que entre los que incluyo el nivel académico, los movimientos ver con la atracción y retención de talento, a todos los asociativos o la industria, puedan aportar el valor que niveles, incluido el de la dirección científica. nos permita seguir construyendo con los profesionales y pacientes el Sistema Sanitario de esta maravillosa región, La investigación y la innovación en el entorno IDIVAL de la mano de la investigación e innovación. deben tener un objetivo rotundamente aplicado y debemos seguir trabajando para desarrollar más y mejores proyectos y para que este esfuerzo retorne a nuestra Sociedad de una manera lo más directa Miguel Rodríguez Gómez posible. Sin duda la innovación, entendida como la Consejero de Sanidad del Gobierno de Cantabria aplicación del conocimiento para generar valor en todas Presidente del Patronato de IDIVAL 10 Memoria de Actividad Prólogo En el año 2019 se ha cumplido el 90 aniversario del Noventa años después hablamos de lo mismo. Hospital. El 24 de octubre de 1929 se inauguró la Casa Valdecilla e IDIVAL siguen fieles a aquel legado de Salud Valdecilla, una estructura moderna con 26 histórico, manteniendo el ADN de la Casa Salud de pabellones para un modelo hospitalario vanguardista Valdecilla. Hace 90 años se recogieron términos que rompió con el concepto de hospitales de la época. (intercambios científicos, trabajos clínicos y de El comienzo de Valdecilla fue excelso con los mejores investigación, congresos médicos españoles e equipos tecnológicos del momento, laboratorios de internacionales, cursos y ciclos de conferencias, investigación experimental, y una clara vocación laboratorio de investigación) que se repiten en la visión de excelencia profesional a través de la formación. y valores de IDIVAL. El Instituto Médico de Postgraduados, junto con el Hospital San Pablo de Barcelona y el Hospital de Regresando al presente, un año más se han cumplido Basurto, constituyó el inicio de la formación de la los objetivos en cuanto a número y calidad de especialidad sanitaria en España. En la misma línea se publicaciones científicas y proyectos de investigación, creó la Escuela de Enfermería y la Biblioteca suscrita a principalmente por el excelente trabajo de los las principales revistas extranjeras y españolas, con un profesionales e investigadores. Además, durante este sistema de becas para estancias en otros hospitales. año 2019 hay dos hechos que quiero destacar por un lado, la primera reacreditación del Instituto, obtenida En 1930 la Gaceta Médica Española publicó una además de forma brillante, tras el nacimiento como amplia entrevista al Dr. López Albo, primer director Instituto de Investigación Sanitaria en 2015; en segundo gerente, que explicaba la filosofía de aquel proyecto. “El lugar, el nombramiento de Marcos López Hoyos como Instituto Médico de Posgraduados aspira a desarrollar director científico del IDIVAL. El Dr. López Hoyos, su labor cultural y docente organizando cursos y fanático racinguista, es un valdecillo de convicción, ciclos de conferencias, a los que serán invitados un excepcional inmunólogo, un entusiasmado y profesores españoles y extranjeros, y manteniendo exitoso investigador traslacional y un gran divulgador. relaciones científicas con los diversos centros culturales En su personalidad profesional múltiple, en su triple médicos de España, de Europa y de América. (…) Se condición de profesor universitario de la Universidad de establecerán intercambios científicos con colegas de Cantabria, jefe de servicio de inmunología de Valdecilla otras provincias españolas y universidades extranjeras. y responsable del grupo de Inmunidad y Trasplante En los Anales de la Casa de Salud Valdecilla se del IDIVAL, se recoge la fuerza de la unión de nuestras publicarán los trabajos clínicos y de investigación Instituciones. A quien corresponda, mi felicitación por el que se vayan realizando
Load more

Recommended publications
  • ( 12 ) United States Patent
    US010376507B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 376 , 507 B2 Srinivasan et al. (45 ) Date of Patent: Aug. 13 , 2019 CRESEMBA® ( isavuconazonium sulfate ) , Highlights of Prescrib (54 ) METHOD OF TREATING A PATIENT WITH ing Information , Label ; Patient Information approved by the U . S . A CYP3A4 SUBSTRATE DRUG Food and Drug Administration ; Astellas Pharma US , Inc. ( Licensed from Basilea Pharmaceutics International Ltd . ) , Illinois, USA , Ini (71 ) Applicant: Bow River LLC , Corona Del Mar , CA tial U . S . Approval: 2015 , Revised Mar. 2015 , Reference ID : 3712237, ( US ) 28 pages . DIFLUCAN® ( fluconazole ), Label ; Patient Information , Reference ( 72 ) Inventors : Sundar Srinivasan , Corona Del Mar, ID : 3650838 , Roerig , Division of Pfizer Inc ., New York , NY, Revised Mar. 2013 , 35 pages. CA (US ) ; Christina Chow , Seattle , WA NIZORAL® (ketoconazole )Label ; Patient Information approved by (US ) the U . S . Food and Drug Administration , Reference ID : 3458324 , Copyright 2014 Janssen Pharmaceuticals, Inc . , New Jersey, USA , ( 73 ) Assignee : BOW RIVER LLC , Corona del Mar , Revised Feb . 2014 , 23 pages . NOXAFIL® (posaconazole ) , Highlights of Prescribing Informa CA (US ) tion , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright © 2006 , 2010 , 2013 , 2014 Merck ( * ) Notice : Subject to any disclaimer , the term of this Sharp & Dohme Corp . , a subsidiary of Merck & Co ., Inc ., New patent is extended or adjusted under 35 Jersey , USA , Revised Sep . 2016 , Reference ID : 3983525, 37 pages . U . S . C . 154 (b ) by 0 days. ORAVIG® (miconazole ) , Highlights of Prescribing Information , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright 2012 Praelia Pharmaceuticals , Inc . , North (21 ) Appl.
    [Show full text]
  • Addyi Generic Name: Flibanserin Manufacturer
    Brand Name: Addyi Generic Name: Flibanserin Manufacturer: Sprout Pharmaceuticals Drug Class: Central Nervous System Agent, Serotonin Agonist, Dopamine antagonist Uses: Labeled Uses: Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Unlabeled Uses: none. Mechanism of Action: The mechanism of action for flibanserin in the treatment of hypoactive sexual desire disorder is unknown. Flibanserin has high affinity for serotonin (5-hydroxytryptamine or 5-HT) 1A receptors, as an agonist, and 5-HT2A receptors, as an antagonist, and moderate affinity for 5- HT2B, 5-HT2C, and dopamine D4 receptors as an antagonist Pharmacokinetics: Absorption: Tmax 0.75 hours Vd 50L t ½ 11 hours Clearance Not reported Protein binding 98% (albumin) Bioavailability 33% Metabolism: Flibanserin is extensively metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19 to at least 35 metabolites, with most of the metabolites occurring in low concentrations in plasma. Elimination: Flibanserin is primarily excreted through the kidneys in to urine (44%) and feces (51%). Two metabolites could be characterized that showed plasma concentration similar to that achieved with flibanserin: 6,21-dihydroxy-flibanserin-6,21-disulfate and 6- hydroxy-flibanserin-6-sulfate. These two metabolites are inactive. Efficacy: Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med.
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • (Flibanserin) (Flibanserin) Tablets
    ™ MEDICATION GUIDE addyi ADDYI™ (add-ee) (flibanserin) (flibanserin) Tablets Read this Medication Guide before you start taking ADDYI™ and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor. What is the most important information I should know about ADDYI? Your risk of severe low blood pressure and fainting (loss of consciousness) is increased if you take ADDYI and: • drink alcohol. Do not drink alcohol if you take ADDYI. • take certain prescription medicines, over-the-counter medicines, or herbal supplements. Do not take or start taking any prescription medicines, over-the-counter medicines, or herbal supplements while taking ADDYI until you have talked with your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI. • have liver problems. Do not take ADDYI if you have liver problems. If you take ADDYI and you feel lightheaded or dizzy, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you faint (lose consciousness). If you faint (lose consciousness), tell your doctor as soon as you can. ADDYI is only available through the ADDYI Risk Evaluation and Mitigation Strategy (REMS) Program because of the increased risk of severe low blood pressure and fainting (loss of consciousness) with alcohol use. You can only get ADDYI from pharmacies that are enrolled in the ADDYI REMS Program. For more information about the Program and a list of pharmacies that are enrolled in the ADDYI REMS Program, go to www.AddyiREMS.com or call 1-844-PINK-PILL (1-844- 746-5745).
    [Show full text]
  • Comparison of Clinical Pharmacology of Voriconazole and Posaconazole 367
    Review Despite greater knowledge and pos- sibilities in pharmacotherapy, fungal infections remain a challenge for cli- nicians. As the population of immu- Comparison of clinical nocompromised patients and those treated for their hematologic ailments pharmacology of voriconazole increases, the number of fungal infec- tions grows too. This is why there is and posaconazole still a quest for new antifungal drugs as well as for optimization of phar- macotherapy with already registered pharmaceutics. Voriconazole and posaconazole are broad-spectrum, new generation, tri- Beata M. Sienkiewicz, Łukasz Łapiński, Anna Wiela-Hojeńska azole antifungal agents. The drugs are used in the pharmacotherapy of Wroclaw Medical University, Wroclaw, Poland invasive aspergillosis, Candida and Fusarium infections. Voriconazole is also used in infections caused by Sce- dosporium. Posaconazole is used in Introduction the treatment of coccidioidomycosis Fungal infections are one of the most severe problems in clinical practice, and chromoblastomycosis. Besides some similarities, the two mentioned especially in hematology and oncology units. They make up from 9 to 10% drugs also show differences in thera- of all infections developing among hospitalized patients. Fungemia can be peutic indications, pharmacokinetics either a complication connected with the malignancy itself or an adverse (mainly absorption and metabolism), effect of the oncological treatment (chemo-, radio- and corticotherapy). Fur- frequency and severity of adverse thermore, it can influence the final
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Noxafil, INN-Posaconazole
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Noxafil 40 mg/mL oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of oral suspension contains 40 mg of posaconazole. Excipients with known effect This medicinal product contains approximately 1.75 g of glucose per 5 mL of suspension. This medicinal product contains 10 mg of sodium benzoate (E211) per 5 mL of suspension. This medicinal product contains up to 1.25 mg of benzyl alcohol per 5 mL of suspension. This medicinal product contains up to 24.75 mg of propylene glycol (E1520) per 5 mL of suspension. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral suspension White suspension 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1): - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products; - Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.
    [Show full text]
  • Cancer and Leukemia Group B
    Protocol Update #11 XX/XX/17 ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY _________________________________________ PROTOCOL UPDATE TO CALGB 10701/CTSU 10701 _________________________________________ A PHASE II STUDY OF DASATINIB (SPRYCEL®) (IND #73969, NSC #732517) AS PRIMARY THERAPY FOLLOWED BY TRANSPLANTATION FOR ADULTS ≥ 18 YEARS WITH NEWLY DIAGNOSED PH+ ACUTE LYMPHOBLASTIC LEUKEMIA BY CALGB, ECOG AND SWOG Investigational Agent: Dasatinib (IND #73969, NSC # 732517 will be supplied by NCI DCTD Companion Studies for Alliance Institutions: CALG 8461 (required), 9665 (optional) Companion Study for ECOG-ACRIN Institutions: E3903 (required) X Update: Status Change: Eligibility changes Activation Therapy / Dose Modifications / Study Calendar changes Closure Informed Consent changes Suspension / temporary closure Scientific / Statistical Considerations changes Reactivation X Data Submission / Forms changes Editorial / Administrative changes Other : Expedited review is allowed. IRB approval (or disapproval) is required within 90 days. Please follow your IRB of record guidelines. UPDATES TO THE PROTOCOL: Section 6.1 Data Submission - In the data submission table, the form “C10701 ABL1 Mutational Analysis Form” has been added prior to “During Treatment (Course I).” This form must be completed for all patients and mailed to the Alliance Statistics and Data Center. - In the data submission table, under “During Treatment (Course VI) and Post-Treatment Follow-Up,” the form “C10701 ABL1 Mutational Analysis Form” has been added. This form must be completed for all patients and mailed to the Alliance Statistics and Data Center. 1 Section 10.13 Filgrastim (G-CSF: Granulocyte Colony-Stimulating Factor; Neupogen; recombinant- methionyl human granulocyte-colony stimulating factor; r-methHuG-CSF; filgrastim-sndz, Zarxio(R)) Zarxio can be used in place of neupogen, therefore, the text “filgrastim-sndz, Zarxio(R)” has been added to the end of the section title.
    [Show full text]
  • Clinical Pearls: Significant Drug Interactions
    8/2/2014 Disclosures • Nothing to disclose Clinical Pearls: Significant Drug Interactions Teresa Kam, PharmD, CPP University of North Carolina Medical Center Learning Objectives Patient Case • Describe the classifications of drug interactions JW is a 43 yo male admitted for newly diagnosed Ph+ B- • Explain clinical outcomes resulting from drug interactions cell ALL • Identify examples and management strategies of drug • Past Medical History • Labs interactions in the oncology population – Hyperlipidemia 138 102 18 106 – Depression 4.1 24 0.96 • Allergies Ca: 8.4 Phos: 4.3 – Penicillin Mg: 2.3 Uric acid: 6.9 LDH: 764 7.1 15.3 16 20.2 ANC: 0.3 Patient Case, cont. Prevalence Induction Chemotherapy Other Medications • At least one potential drug-drug interaction found in 27-58% • Dasatinib • Allopurinol of ambulatory cancer patients • Cyclophosphamide + Mesna • Levofloxacin (prophylaxis) • At least one potential severe drug interaction involving • Vincristine • Pantoprazole chemotherapy found in 14% of patients ≥70 years old • Doxorubicin • Posaconazole (prophylaxis) • At least one potential drug-drug interaction in 46% of patients • Dexamethasone • Sertraline receiving oral anticancer drugs • IT Cytarabine + • Simvastatin • Drug-drug interactions estimated to be cause of approximately 4% of deaths Hydrocortisone • Valacyclovir (prophylaxis) • IT Methotrexate + • Ondansetron premed + prn Hydrocortisone • Prochlorperazine prn Popa MA, et al. J Geriatr Oncol 2014; http://dx.doi.org/10.1016/j.jgo.2014.04.002. Van Leeuwen RW, et al. Br J Cancer
    [Show full text]
  • Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from in Vitro Inhibition of Metabolism
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from In Vitro Inhibition of Metabolism Author(s): David E. Moody, Ph.D. Document No.: 250127 Date Received: July 2016 Award Number: 2011-DN-BX-K532 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this federally funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. February 2016 Research and Development in Forensic Toxicology Prediction of drug interactions with methadone, buprenorphine and oxycodone from in vitro inhibition of metabolism Final Technical Report Submitted electronically to: U.S. Department of Justice Office of Justice Programs National Institute of Justice Prepared by: David E. Moody. Ph.D. Director of the Center for Human Toxicology, and Research Professor of Pharmacology and Toxicology [email protected] / 801-581-5117 NIJ Award Number: 2011-DN-BX-K532 Reporting Period: January 1, 2012 to December 31, 2015 Recipient Organization: University of Utah 75 South 2000 East, Room 222 Salt Lake City, UT 84112-8930 Organizational DUNS: 0090953650000 EIN: 876000525 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics
    Supplementary Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs–Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Table S1. Possible drug-drug interactions of lasmiditan [14,28,31,35–38,40,42,45–47]. The risk or severity of Serum concentration of the Serum concentration of Lasmiditan may serotonin syndrome can following drugs (P-gp lasmiditan (P-gp substrate) increase the be potentially increased and/or BCRP substrates) may potentially increase bradycardic when lasmiditan is may potentially increase when it is combined with effects of the combined with the when combined with the following drugs3,. following drugs. following drugs1,. lasmiditan2,. 5-hydroxytryptophan* afatinib acebutolol alfentanil* alpelisib amlodipine almotriptan* ambrisentan atenolol amitriptiline* apixaban betaxolol amoxapine* belinostat carteolol buspirone* bisoprolol carvedilol citalopram* brentuximab vedotin diltiazem clomipramine* cabazitaxel esmolol cyclobenzaprine* ceritinib felodipine desipramine* cladribine isradipine desvenlavaxine* cobimetinib clobazam ivabradine dexfenfluramine* colchicine* daclatasvir labetalol dextromethorphan* cyclosporine erythromycin levobetaxolol dihydroergotamine* daunorubicin fexofenadine levobunolol dolasetron* delafloxacin lapatinib methyldopa doxepin* digitoxin ritonavir metipranolol doxepin topical* digoxin metoprolol duloxetine* donepezil nadolol eletriptan* doxorubicin nebivolol ergotamine* edoxaban* nicardipine escitalopram*
    [Show full text]
  • Attachment: Product Information: Ranolazine
    Attachment 1: Product information for AusPAR - AusPAR RANEXA ranolazine – A Menarini Australia Pty Ltd PM-2015-00423-1-3 FINAL 20 February 2018 This Product information was approved at the time this AusPAR was published. PRODUCT INFORMATION RANEXA® MODIFIED-RELEASE TABLETS NAME OF THE MEDICINE Ranolazine Chemical Structure Ranolazine is designated chemically as (±)-N-(2,6-dimethylphenyl)4-[2-hydroxy-3-(2- methoxyphenoxy)propyl] piperazineacetamide. The empirical formula for ranolazine is C24H33N3O4 with a molecular weight of 427.54. CAS number 95635-55-5 DESCRIPTION Ranolazine is a white to off-white solid powder. Ranolazine is soluble in dichloromethane and methanol; sparingly soluble in tetrahydrofuran, ethanol, acetonitrile, and acetone; slightly soluble in ethyl acetate, isopropanol, toluene, and ethyl ether; and very slightly soluble in water. Ranolazine is very slightly soluble at pH above 6.99, slightly soluble at pH from 6.29 to 5.76, sparingly soluble at pH 5.25, soluble at pH from 5.01 to 4.82 and freely soluble below pH 4.40. The partition coefficient was determined using three different ratios of octanol: water. The log P for ranolazine was measured at 2.07 ± 0.06. RANEXA 375 mg, 500 mg and 750 mg tablets contain the following inactive ingredients: carnauba wax, hypromellose, magnesium stearate, methacrylic acid-ethyl acrylate copolymer (1:1), microcrystalline cellulose, sodium hydroxide and titanium dioxide. Additional inactive ingredients for the 375 mg tablet include: macrogol, polysorbate 80, indigo carmine aluminium lake. Additional inactive ingredients for the 500 mg tablet include: macrogol, polyvinyl alcohol, iron oxide yellow, iron oxide red, purified talc.
    [Show full text]